Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia

Central Nervous System Tumors

Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N, SHH type and poor survival independent of treatment strategies

Neuro Oncol

Sönksen M, Obrecht-Sturm D, Hernáiz Driever P, Sauerbrey A, Graf N, Kontny U, Reimann C, Langhein M, Kordes UR, Schwarz R, Obser T, Boschann F, Schüller U, Altendorf L, Goschzik T, Pietsch T, Mynarek M, Rutkowski S

doi: 10.1093/neuonc/noae111

Lung, Respiratory and Thoracic Cancer

Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non-Small Cell Lung Cancer With High Programmed Death-Ligand 1 Expression

JTO Clin Res Rep

Cheung AHK, Mui Z, Yeung WW, Chow C, Yu MF, Chen OH, Wong KY, Xie F, Lau YM, Cheng AS, Kang W, To KF, Mok TS, Li MSC

doi: 10.1016/j.jtocrr.2024.100754

Gastrointestinal Cancer

An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study

Clin Cancer Res

Xu C, Mannucci A, Esposito F, Oliveres H, Alonso Orduña V, Yubero A, Fernández-Martos C, Salud A, Gallego J, Martin-Richard M, Fernández-Plana J, Guillot M, Aparicio J, Fakih M, Kopetz S, Feliu J, Maurel J, Goel A

doi: 10.1158/1078-0432.CCR-24-1934

Genitourinary Cancer

Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial

Eur J Cancer

Roy S, Saad F, Sun Y, Malone S, Spratt DE, Kishan AU, Wallis CJD, Jia AY, Mohamad O, Swami U, Ong M, Agarwal N, Chowdhury S, Morgan SC

doi: 10.1016/j.ejca.2024.114197

Lung, Respiratory and Thoracic Cancer

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

J Thorac Oncol

Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT

doi: 10.1016/j.jtho.2024.09.1443

Lung, Respiratory and Thoracic Cancer

Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: Real-world outcomes from the GuardantINFORM database

J Thorac Oncol

Parikh K, Dimou A, Leventakos K, Mansfield AS, Shanshal M, Wan Y, Lin HM, Vincent S, Elliott J, Bonta IR

doi: 10.1016/j.jtho.2024.07.009

Central Nervous System Tumors

Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment

Neuro Oncol

Obrecht-Sturm D, Schömig L, Mynarek M, Bison B, Schwarz R, Pietsch T, Pfister SM, Sill M, Sturm D, Sahm F, Kortmann RD, Gerber NU, von Bueren AO, Fleischhack G, Schüller U, Nussbaumer G, Benesch M, Rutkowski S

doi: 10.1093/neuonc/noae071

ASH 2024

Leukemia

AMPLIFY: Superior PFS with acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy in patients with treatment-naïve CLL

ASCO 2024

Breast Cancer

Related content

Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N, SHH type and poor survival independent of treatment strategies

Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non-Small Cell Lung Cancer With High Programmed Death-Ligand 1 Expression

An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study

Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: Real-world outcomes from the GuardantINFORM database

Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment

AMPLIFY: Superior PFS with acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy in patients with treatment-naïve CLL

Pooled analysis of DESTINY-Breast01, -02 and -03: Patients with objective response to T-DXd achieved prolonged survival